JP2021510174A5 - - Google Patents
Info
- Publication number
- JP2021510174A5 JP2021510174A5 JP2020557124A JP2020557124A JP2021510174A5 JP 2021510174 A5 JP2021510174 A5 JP 2021510174A5 JP 2020557124 A JP2020557124 A JP 2020557124A JP 2020557124 A JP2020557124 A JP 2020557124A JP 2021510174 A5 JP2021510174 A5 JP 2021510174A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- use according
- interaction
- seq
- affects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024097199A JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614262P | 2018-01-05 | 2018-01-05 | |
| US62/614,262 | 2018-01-05 | ||
| US16/184,129 US20190194290A1 (en) | 2010-10-19 | 2018-11-08 | Methods for preventing, modulating and/or reducing cardiovascular disease |
| US16/184,129 | 2018-11-08 | ||
| PCT/US2019/012425 WO2019136307A1 (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024097199A Division JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510174A JP2021510174A (ja) | 2021-04-15 |
| JP2021510174A5 true JP2021510174A5 (enExample) | 2023-06-19 |
| JP7511242B2 JP7511242B2 (ja) | 2024-07-05 |
Family
ID=67144298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557124A Active JP7511242B2 (ja) | 2018-01-05 | 2019-01-04 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
| JP2024097199A Pending JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024097199A Pending JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3735260B1 (enExample) |
| JP (2) | JP7511242B2 (enExample) |
| CN (2) | CN111801110B (enExample) |
| AU (1) | AU2019205328B2 (enExample) |
| BR (1) | BR112020013716A2 (enExample) |
| CA (1) | CA3086193A1 (enExample) |
| MX (1) | MX2020007081A (enExample) |
| SG (1) | SG11202006494VA (enExample) |
| WO (1) | WO2019136307A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012054584A2 (en) | 2010-10-19 | 2012-04-26 | The Regents Of The University Of Colorado, A Body Corporate | Peptides for modulating t-cell activity and uses thereof |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
| US12048734B2 (en) | 2020-04-17 | 2024-07-30 | Op-T Llc | Bioactive peptides and methods of use thereof |
| WO2021231898A2 (en) * | 2020-05-14 | 2021-11-18 | Op-T Llc | Nanoparticle compositions and uses thereof |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CN117471100B (zh) * | 2022-07-22 | 2026-05-01 | 暨南大学 | Th40细胞亚群在制备辅助诊断和评估系统性红斑狼疮疾病活动试剂盒中的应用 |
| CN115807071B (zh) * | 2022-09-02 | 2025-09-26 | 宁夏医科大学 | 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| CA2542984A1 (en) * | 2003-07-07 | 2005-01-27 | David H. Wagner | Methods for predicting development of auto-immune diseases and treatment of same |
| US7449200B2 (en) * | 2006-04-17 | 2008-11-11 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means |
| WO2012054584A2 (en) * | 2010-10-19 | 2012-04-26 | The Regents Of The University Of Colorado, A Body Corporate | Peptides for modulating t-cell activity and uses thereof |
| CN104619722B (zh) * | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
| WO2015148389A2 (en) * | 2014-03-23 | 2015-10-01 | The Regents Of The University Of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
-
2019
- 2019-01-04 EP EP19736089.4A patent/EP3735260B1/en active Active
- 2019-01-04 BR BR112020013716-2A patent/BR112020013716A2/pt unknown
- 2019-01-04 CA CA3086193A patent/CA3086193A1/en active Pending
- 2019-01-04 CN CN201980017176.9A patent/CN111801110B/zh active Active
- 2019-01-04 AU AU2019205328A patent/AU2019205328B2/en active Active
- 2019-01-04 MX MX2020007081A patent/MX2020007081A/es unknown
- 2019-01-04 JP JP2020557124A patent/JP7511242B2/ja active Active
- 2019-01-04 WO PCT/US2019/012425 patent/WO2019136307A1/en not_active Ceased
- 2019-01-04 SG SG11202006494VA patent/SG11202006494VA/en unknown
- 2019-01-04 CN CN202411324616.4A patent/CN119157997A/zh active Pending
-
2024
- 2024-06-17 JP JP2024097199A patent/JP2024123100A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183389A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| KR20160009575A (ko) | 심부전을 치료하기 위한 뉴레귤린의 연장 방출 | |
| JP7759724B2 (ja) | エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用 | |
| JP2020502151A5 (enExample) | ||
| US20190038769A1 (en) | Micro-rna profiling, compositions, and methods of treating diseases | |
| TW201522629A (zh) | 提供治療多肽之持續遞送的微器官及其使用方法 | |
| JP7074300B2 (ja) | ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療 | |
| US20170348393A1 (en) | Treatment of cns inflammatory disorders | |
| Fargnoli | Secukinumab: The anti-IL-17A biologic for the treatment of psoriasis | |
| Schmid et al. | New strategies for managing anemia of chronic kidney disease | |
| CN106138098B (zh) | 自然杀伤细胞联合抗抑郁药在改善抑郁症状中的应用 | |
| CN116966302A (zh) | Areg的新用途 | |
| CN115487292A (zh) | 一种治疗糖尿病的联合用药物及其应用 | |
| TWI359030B (en) | Treatment of cellular proliferative disorders | |
| CN103656639B (zh) | 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途 | |
| JP2018500882A5 (enExample) | ||
| CN115813925B (zh) | Acbi1的应用 | |
| US20130102662A1 (en) | Use of inducible nitric oxide synthase inhibitors and nitric oxide scavengers to inhibit post-traumatic immunodepression | |
| Butt et al. | Abstract# 1394569: Efficacy and Safety of Empagliflozin: Real-World Tertiary Center Experience from the Kingdom of Saudi Arabia | |
| Perry | HUMAN LEUKEMIA-AN OVERVIEW | |
| WO2022201168A1 (en) | Methods and compositions for treating or preventing a disease or a condition | |
| CN121926929A (zh) | Erg抑制剂在制备治疗/改善肥胖、脂肪肝的药物中的应用 | |
| CN104001189A (zh) | 一种p53基因、p53蛋白和基因重组药物的应用 | |
| CN121622893A (zh) | Tbx1基因表达在肿瘤治疗中的应用 |